Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215858 · ClinicalTrials.gov registry record · Phase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT07215858 is a Phase 2 study that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 129 participants.
The verdict
NCT07215858, a Phase 2 study, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital. ...
Interventions
- BIOLOGICAL BPL-1357 IM
- BIOLOGICAL BPL-1357 IN
- OTHER Placebo IM
- OTHER Placebo IN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215858
The ClinicalTrials.gov registry entry for NCT07215858 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BPL-1357 IM is the first listed.
NCT07215858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07215858 about?
NCT07215858 is a clinical study titled "BPL-1357 Against H1N1 Influenza Virus Challenge". Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: T...
What is the current status of trial NCT07215858?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2026-07-15. Estimated completion is 2028-03-01.
What interventions are being tested in trial NCT07215858?
The interventions under investigation include: BPL-1357 IM (BIOLOGICAL), BPL-1357 IN (BIOLOGICAL), Placebo IM (OTHER), Placebo IN (OTHER).
Who is sponsoring clinical trial NCT07215858?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.